23rd Annual International Congress on the Future of Breast Cancer® West

Breakfast & Non-CME Product Theater: A Novel 2L Treatment Option for HR+/HER2− aBC or mBC With PIK3CA/AKT1/PTEN Alterations

Welcome, Introductions, and Presession Survey

Immunotherapy for High Risk Early Stage Breast Cancer

Premenopausal HR+ Early Breast Cancer: What to do outside the OFSET Trial?

Practical Application of CDK 4/6 Inhibitor Therapy in Early and Metastatic Breast Cancer

New Insights into Optimizing HER2-Directed Therapy in the Curative Setting

Ameliorating Treatment-Limiting Toxicities

Progress and Challenges in Monitoring for Molecular Residual Disease in EBC

Biology and Management of Inflammatory Breast Cancer

Lunch & Non-CME Product Theater: Treatment Considerations for Endocrine-Sensitive Patients With HR+/HER2 - Metastatic Breast Cancer

Novel Therapies Targeting the Estrogen Receptor

New Therapeutic Strategies for HER2+ Metastatic Disease Including Brain Metastases

How to Effectively Inhibit the PI3K/AKT Pathway

Current and Future Landscape of Antibody Drug Conjugates

Implications of Mainstreaming Germline Genetic Testing in Oncology Practice

Innovative Strategies to Improve Triple Negative Breast Cancer Outcomes

Dinner & Non-CME Product Theater: Explore the Current Data That Could Help You Recognize/Assess Candidates for a CDK4 & 6 Inhibitor

Breakfast & Non-CME Product Theater: HER2 Expression and Eligibility in HER2+ and HER2-Low mBC

New Biologic Subtypes and Therapeutic Insights from I-SPY2

Less Surgery and More Radiation Therapy in Locoregional Breast Cancer Management

Giants of Cancer Care Award Lecture: Tailoring Locoregional Management with Neoadjuvant Chemotherapy

Who Needs More Than Axillary Sentinel Lymph Node Surgery?

Endocrine Therapy vs Radiation Therapy vs Both in Postmenopausal Breast Cancer

Conventional vs Hypofractionated Radiotherapy: Best Practices

Locoregional Management of Invasive Lobular Breast Cancer

New Approaches for Decreasing Risk of Lymphedema

Omission of Surgery After Neoadjuvant Chemotherapy: Are We There Yet?

After NSABP B51, Should RT Be Omitted in All Node-Positive Patients Who Are Converted to N0?

Case Discussions From Faculty Practices/Q&A Session

Lunch & OncLive® Seminar:  Optimizing Later Lines of Therapy in HER2+ Metastatic Breast Cancer

Improving Sexual Health During Breast Cancer Treatment

Understanding ctDNA Results to Sequence Therapies in Metastatic Breast Cancer

Ovarian Preservation, Assisted Reproduction, Fertility and Pregnancy in Early Breast Cancer

Breaking the Link Between Obesity and Worse Breast Cancer Outcomes

Update on Biologic and Therapeutic Insights into Invasive Lobular Breast Cancer